Guilin Sanjin announcement: The BC011 monoclonal antibody injection of its subsidiary Baochuan Bio has obtained the clinical trial approval notice issued by the National Medical Products Administration, and it is allowed to conduct clinical trials in advanced solid tumors. The drug is independently developed by Baochuan Bio and has strong anti-tumor activity and good safety. Baochuan Bio will conduct clinical trials in China in accordance with national drug regulations and requirements.
桂林三金：控股孙公司BC011抗体注射液获临床试验批准
Guilin Sanjin: Its subsidiary BC011 monoclonal antibody injection has been approved for clinical trials.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.